SEARCH

SEARCH BY CITATION

Keywords:

  • Antiepileptic drugs;
  • Mode of action;
  • Glutamate;
  • Perampanel

Summary

With perampanel the first-in-class selective alpha-amino-3-hydroxy-5-methyl-4-isoxazolprepionic acid (AMPA) receptor antagonist has been finally approved for add-on treatment in patients with focal-onset seizures. This suggests additional therapeutic potential in hitherto difficult-to-treat epilepsies.